KRAS and neoplasm: As the combination of KRAS ASO and immRNA in RBCEVs displayed a high ability to upregulate the expression of IFNs and induce tumor cell death in both in vitro and in vivo settings, we studied the induction of immunogenic cell death effect in vivo by quantifying the DC maturation markers (CD86) in tumor-draining lymph node (tdLNs) and the formation of effector memory T cells in the spleen.